Oryzon Genomics SA
MAD:ORY

Watchlist Manager

Oryzon Genomics SA

MAD:ORY

Watchlist

Dividends

Discount Rate

Price: 1.654 EUR 0.98% Market Closed

Market Cap: 105.5m EUR

Have any thoughts about
Oryzon Genomics SA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Estee Lauder Companies Inc NYSE:EL	Consumer products
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Church & Dwight Co Inc NYSE:CHD	Consumer products
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	American Express Co NYSE:AXP	Financial Services
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Target Corp NYSE:TGT	Retail
US	Walt Disney Co NYSE:DIS	Media
US	Mueller Industries Inc NYSE:MLI	Machinery
US	PayPal Holdings Inc NASDAQ:PYPL	Technology

Add Price Alert

Price Target:

Last Price: 1.654 EUR

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

ORY Alert

Oryzon Genomics SA

1.654

+0.016 (+0.98%)

52 Week Range	1.602 2.215
Price Target

We'll email you a reminder when the closing price reaches EUR.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Estee Lauder Companies Inc NYSE:EL	US
	Exxon Mobil Corp NYSE:XOM	US
	Church & Dwight Co Inc NYSE:CHD	US
	Pfizer Inc NYSE:PFE	US
	American Express Co NYSE:AXP	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Target Corp NYSE:TGT	US
	Walt Disney Co NYSE:DIS	US
	Mueller Industries Inc NYSE:MLI	US
	PayPal Holdings Inc NASDAQ:PYPL	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Oryzon Genomics SA

What unique competitive advantages
does Oryzon Genomics SA hold over its rivals?

What risks and challenges
does Oryzon Genomics SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Oryzon Genomics SA.

What unique competitive advantages
does Oryzon Genomics SA hold over its rivals?

What risks and challenges
does Oryzon Genomics SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Oryzon Genomics SA.

Provide P/S
for Oryzon Genomics SA.

Provide P/E
for Oryzon Genomics SA.

Provide P/OCF
for Oryzon Genomics SA.

Provide P/FCFE
for Oryzon Genomics SA.

Provide P/B
for Oryzon Genomics SA.

Provide EV/S
for Oryzon Genomics SA.

Provide EV/GP
for Oryzon Genomics SA.

Provide EV/EBITDA
for Oryzon Genomics SA.

Provide EV/EBIT
for Oryzon Genomics SA.

Provide EV/OCF
for Oryzon Genomics SA.

Provide EV/FCFF
for Oryzon Genomics SA.

Provide EV/IC
for Oryzon Genomics SA.

Show me price targets
for Oryzon Genomics SA made by professional analysts.

What are the Revenue projections
for Oryzon Genomics SA?

How accurate were the past Revenue estimates
for Oryzon Genomics SA?

What are the Net Income projections
for Oryzon Genomics SA?

How accurate were the past Net Income estimates
for Oryzon Genomics SA?

What are the EPS projections
for Oryzon Genomics SA?

How accurate were the past EPS estimates
for Oryzon Genomics SA?

What are the EBIT projections
for Oryzon Genomics SA?

How accurate were the past EBIT estimates
for Oryzon Genomics SA?

Compare the revenue forecasts
for Oryzon Genomics SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Oryzon Genomics SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Oryzon Genomics SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Oryzon Genomics SA compared to its peers.

Compare the P/E ratios
of Oryzon Genomics SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Oryzon Genomics SA with its peers.

Analyze the financial leverage
of Oryzon Genomics SA compared to its main competitors.

Show all profitability ratios
for Oryzon Genomics SA.

Provide ROE
for Oryzon Genomics SA.

Provide ROA
for Oryzon Genomics SA.

Provide ROIC
for Oryzon Genomics SA.

Provide ROCE
for Oryzon Genomics SA.

Provide Gross Margin
for Oryzon Genomics SA.

Provide Operating Margin
for Oryzon Genomics SA.

Provide Net Margin
for Oryzon Genomics SA.

Provide FCF Margin
for Oryzon Genomics SA.

Show all solvency ratios
for Oryzon Genomics SA.

Provide D/E Ratio
for Oryzon Genomics SA.

Provide D/A Ratio
for Oryzon Genomics SA.

Provide Interest Coverage Ratio
for Oryzon Genomics SA.

Provide Altman Z-Score Ratio
for Oryzon Genomics SA.

Provide Quick Ratio
for Oryzon Genomics SA.

Provide Current Ratio
for Oryzon Genomics SA.

Provide Cash Ratio
for Oryzon Genomics SA.

What is the historical Revenue growth
over the last 5 years for Oryzon Genomics SA?

What is the historical Net Income growth
over the last 5 years for Oryzon Genomics SA?

What is the current Free Cash Flow
of Oryzon Genomics SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Oryzon Genomics SA.

EV/EBITDA
Enterprise Value to EBITDA

-23.5

Current

-24.5

Median

4.3

Industry

Higher than median

Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA

-23.5

Enterprise Value

102m EUR

EBITDA

-4.3m EUR

All Countries

Forward Multiples

			Market Cap	EV/EBITDA
ES		Oryzon Genomics SA MAD:ORY	104.1m EUR	-23.5
FR		Pharnext SCA OTC:PNEXF	6T USD	-216 796.7
US		Abbvie Inc NYSE:ABBV	300.2B USD	14.8
US		Amgen Inc NASDAQ:AMGN	158.7B USD	17.5
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	126.8B USD	26.8
US		Gilead Sciences Inc NASDAQ:GILD	115B USD	10.1
US	E	Epizyme Inc F:EPE	94.1B EUR	-521.2
AU		CSL Ltd ASX:CSL	137.3B AUD	20.8
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	88.3B USD	17.4
US	S	Seagen Inc F:SGT	39.3B EUR	-59.5
NL		argenx SE XBRU:ARGX	34.1B EUR	-104.5

				EBITDA Growth
ES		Oryzon Genomics SA MAD:ORY	Average EV/EBITDA: 17.9 Negative Multiple: -23.5	N/A
FR		Pharnext SCA OTC:PNEXF	Negative Multiple: -216 796.7	N/A
US		Abbvie Inc NYSE:ABBV	14.8	28%
US		Amgen Inc NASDAQ:AMGN	17.5	63%
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	26.8	38%
US		Gilead Sciences Inc NASDAQ:GILD	10.1	12%
US	E	Epizyme Inc F:EPE	Negative Multiple: -521.2	N/A
AU		CSL Ltd ASX:CSL	20.8	42%
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	17.4	46%
US	S	Seagen Inc F:SGT	Negative Multiple: -59.5	N/A
NL		argenx SE XBRU:ARGX	Negative Multiple: -104.5	N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

EV/EBITDA

-23.9

2-Years Forward

EV/EBITDA

82.8

3-Years Forward

EV/EBITDA

-21.2

Oryzon Genomics SA
MAD:ORY

EV/EBITDA
Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

Oryzon Genomics SA MAD:ORY

EV/EBITDA Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

Oryzon Genomics SA
MAD:ORY

EV/EBITDA
Enterprise Value to EBITDA